Objective:

To explore how cell and gene therapy (CGT) companies, payers, and healthcare systems are rethinking pricing and reimbursement models for advanced therapies.

Approach:

• Industry Perspectives: Insights from various leaders in the CGT field discussing the need for new reimbursement models.

Key Findings:

• High upfront costs of one-time curative therapies challenge traditional reimbursement models.
• Long-term benefits, including reduced hospitalizations and improved quality of life, should be considered in value assessments.
• Outcomes-based agreements and staged payments are discussed as potential solutions for aligning costs with therapy value.

Interpretation:

The discussion highlights the need for reimbursement models that reflect the long-term impact of advanced therapies as emphasized by industry leaders.

Limitations:

• The article does not provide specific data or case studies from the discussions to support the claims made.
• No detailed analysis of the effectiveness of proposed reimbursement models is included in the insights shared.

Conclusion:

The sector is actively seeking ways to improve access to high-value therapies through innovative reimbursement strategies.

Sources:

• ARM's Meeting on the Med 2026